Vasomotor symptoms in aging Chinese women: findings from a prospective cohort study

Li, J; Luo, Meiling; Tang, Ruiyi; Sun, Xiangyu; Wang, Y; Liu, B; Cui, Jian‐Fang; Liu, G; Lin, Shen; Chen, R

doi:10.1080/13697137.2019.1628734

Cited by 14 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is comparable with findings from the Pan-Asia menopause study, where hot flashes ranged from 45.7% to 72.2% and night sweats from 28.4% to 39.9% among symptomatic women 15 . Additionally, in a study in China, 83.4% reported hot flashes and 82.9% night sweats 3 . Other studies have reported lower prevalence rates (<60%), and were subject to notable limitations due to reporting mechanisms and the use of non-representative samples 4,16-18 .…”

Section: Discussionsupporting

confidence: 85%

Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause

Chae

Hsiao

et al. 2022

Menopause

View full text Add to dashboard Cite

Objective: To understand prevalence, severity, impact, and treatment of vasomotor symptoms associated with menopause, using cross-sectional survey data. Methods: This online, two-part survey was conducted in East Asia among women 40-65 years recruited from established online panels (Edelman, Beijing; Hankook Research, Seoul; Rakuten Insight, Taipei) using stratified sampling. Part I collected demographics/disease characteristics, including menopausal status and vasomotor symptom severity. Women with moderate-to-severe vasomotor symptoms completed Part II, including clinical characteristics, health-related quality of life, and healthcare-seeking behavior. Primary endpoints included vasomotor symptom prevalence and severity and proportions of women eligible and willing to take hormone therapy. Results are presented for each of the three online panels separately and as a pooled total. All analyses are descriptive with no formal hypothesis testing across groups. Results: Numbers of peri- versus postmenopausal women completing Part I were Edelman, 1,588 (55.1% vs 44.9%); Hankook Research, 1,000 (43.6% vs 56.4%); Rakuten Insight, 773 (61.7% vs 38.3%). Vasomotor symptom prevalence was =80% in each region; overall moderate-to-severe vasomotor symptom prevalence was 55%; >50% of women were untreated. Most of those treated used non-prescription treatments. Menopausal hormone therapy use was reported by 11.6% of peri- and 7.2% of postmenopausal women. In peri- and postmenopausal women with moderate-to-severe vasomotor symptoms, 8.6% and 3.4%, respectively, were hormone therapy-willing, 19.3% and 16.8% hormone therapy-contraindicated, 25.4% and 23.0% hormone therapy-cautious, and 10.2% and 8.3% hormone therapy-averse. Women experienced significant burden on health-related quality of life and substantial impairment of work productivity and daily activities. Conclusions: Vasomotor symptoms associated with menopause affected =80% of women aged 40 to 65 years. A substantial proportion of women are unsuitable for, or choose not to take, menopausal hormone therapy, resulting in an unmet need for nonhormonal treatment options.

show abstract

Section: Discussionsupporting

confidence: 85%

Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause

Chae

Hsiao

et al. 2022

Menopause

View full text Add to dashboard Cite

show abstract

“…Hot flash treatment is equally effective in the conjugated oestrogen and 17β-oestradiol regimen in the Women's Health Initiative and Heart and Oestrogen/progestin Replacement Study [21]. The main hormone affecting the QOL in postmenopausal women who have hot flashes from vasomotor symptoms is oestrogen [22]. Hot flashes decreased when the hormone therapy was started in this study.…”

Section: Discussionmentioning

confidence: 79%

The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women

Gocer¹,

Güven²,

Şal³

et al. 2021

View full text Add to dashboard Cite

“…A recent longitudinal cohort study of 187 women in China demonstrated a higher prevalence of symptoms versus previous studies in Chinese women, reporting that 83.4% experienced hot flushes and 82.9% experienced night sweats [9]. This cohort study did support previous reports that Chinese women may experience symptoms for a shorter time, with a median duration of 4.5 years for hot flushes and night sweats [9], compared with 7.4-10.2 years in studies of vasomotor symptoms in predominantly Caucasian and African American women [10,11]. The reasons behind ethnic differences are not fully understood but likely include cultural, lifestyle, genetic, psychosocial and perceptual factors [2].…”

Section: Introductionmentioning

confidence: 70%

“…However, the full picture is unclear as data are sparse in non-Caucasian populations, and most reports in Asian women have not examined the prevalence of symptoms prospectively [3,[6][7][8]. A recent longitudinal cohort study of 187 women in China demonstrated a higher prevalence of symptoms versus previous studies in Chinese women, reporting that 83.4% experienced hot flushes and 82.9% experienced night sweats [9]. This cohort study did support previous reports that Chinese women may experience symptoms for a shorter time, with a median duration of 4.5 years for hot flushes and night sweats [9], compared with 7.4-10.2 years in studies of vasomotor symptoms in predominantly Caucasian and African American women [10,11].…”

Section: Introductionmentioning

confidence: 96%

“…This is also reflected in the Chinese guideline on menopause management and hormone therapy, which recommends MHT for the treatment of vasomotor symptoms within 10 years following menopause [15]. The long duration of vasomotor symptoms reported across ethnic groups [9][10][11] supports the need for therapies that can be better tailored to each woman's needs and, therefore, low-dose options may be particularly appealing.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China

Ren

Ruan

et al. 2021

Climacteric

View full text Add to dashboard Cite

Objective: This study aimed to evaluate the efficacy and safety of ultra-low-dose estradiol plus dydrogesterone for vasomotor symptoms in postmenopausal women in China (trial registration CTR20160689). Methods: A total of 332 patients were randomized to continuous combined estradiol 0.5 mg þ dydrogesterone 2.5 mg or placebo for 12 weeks. The primary efficacy endpoint was change in the number of hot flushes per day from baseline to end of treatment. Secondary efficacy endpoints included change in the number of moderate-to-severe hot flushes per day, menopausal symptoms from baseline and quality of life. Results: Between baseline and end of treatment, change in the mean number of hot flushes per day was À5.9 (95% confidence interval [CI] À 6.6, À5.2) with estradiol þ dydrogesterone and À4.5 (95% CI À5.1, À3.8) with placebo, with a mean difference of À1.4 hot flushes per day (95% CI À2.2, À0.7; p < 0.001). Significant differences in favor of estradiol þ dydrogesterone were also observed in several secondary efficacy endpoints. The study treatment was well tolerated. Conclusion: Continuous combined estradiol 0.5 mg þ dydrogesterone 2.5 mg reduced hot flushes in postmenopausal women in China. This ultra-low-dose regimen provides an additional option for women experiencing the vasomotor symptoms of menopause. These data are consistent with previous results in other populations.

show abstract

Vasomotor symptoms in aging Chinese women: findings from a prospective cohort study

Cited by 14 publications

References 42 publications

Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause

Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause

The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women

Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China

Contact Info

Product

Resources

About